W
WAVEMAN · COMPANY
MLTX · Moonlake Immunotherapeutics
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

MLTX

MoonLake Immunotherapeutics
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001821586
FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-$77.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
115
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$77.0M over 180 days
-$9.3M over 90 days · -$63.0M of it by a 10%+ holder
below 97% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
115 funds added or opened last quarter
more than 71% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
6.7% of shares outstanding short · 6.6 days to cover · settled 2026-07-31
more than 63% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$77.0M across 4 people in 180 days.
115 funds added or opened positions in the latest 13F quarter, of 173 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -74.1%
-74.1%12M
-89%-58%-26%+6%2025-092025-102025-122026-032026-052026-072026-09 2026-03-31 · LAMPERT MARK N sold $32.4M2026-03-31 · LAMPERT MARK N sold $26.3M2025-09-29 · Cormorant Global Healthcare Master Fund, LP sold $25.7M2025-09-29 · Cormorant Global Healthcare Master Fund, LP sold $18.5M2026-03-31 · LAMPERT MARK N sold $4.2M2025-12-08 · Santos da Silva Jorge sold $2.0M2025-12-08 · Reich Kristian sold $2.0M2025-09-29 · Cormorant Global Healthcare Master Fund, LP sold $2.0M2026-04-10 · Santos da Silva Jorge sold $1.8M2026-04-09 · Bodenstedt Matthias sold $1.6M2026-07-10 · Santos da Silva Jorge sold $1.4M2025-12-09 · Reich Kristian sold $1.1M2025-12-09 · Santos da Silva Jorge sold $1.0M2026-07-21 · Reich Kristian sold $1.0M2026-06-17 · Reich Kristian sold $971.5K2026-07-01 · Santos da Silva Jorge sold $956.9K2026-04-13 · Santos da Silva Jorge sold $945.6K2026-06-15 · Reich Kristian sold $944.5K2026-06-16 · Reich Kristian sold $935.0K2026-07-20 · Reich Kristian sold $877.9K2026-06-22 · Bodenstedt Matthias sold $862.2K2026-07-09 · Santos da Silva Jorge sold $679.1K2025-09-29 · Cormorant Global Healthcare Master Fund, LP sold $663.6K2026-07-15 · Reich Kristian sold $322.3K2026-06-17 · Bodenstedt Matthias sold $296.8K2026-05-11 · Bodenstedt Matthias sold $273.3K2025-10-08 · Bodenstedt Matthias bought $98.8K2026-06-18 · Bodenstedt Matthias sold $54.8K2026-07-22 · Reich Kristian sold $49.0K2026-04-14 · Bodenstedt Matthias sold $47.5K2025-09-30 · Cormorant Global Healthcare Master Fund, LP sold $40.6K2026-04-10 · Bodenstedt Matthias sold $37.6K2026-07-27 · Reich Kristian sold $22.0K2026-07-15 · Reich Kristian filed to sell $2.9M2026-06-30 · Santos da Silva Jorge filed to sell $3.0M
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $77.0M sold by insiders over 180 days, 115 funds added last quarter, $5.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, MoonLake Immunotherapeutics insiders sold a net $77.0M of stock across 97 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Reich Kristian
Chief Scientific Officer
SELL
2026-07-27
1,100.0
$22.0K
Reich Kristian
Chief Scientific Officer
SELL
2026-07-22
2,448.0
$49.0K
Reich Kristian
Chief Scientific Officer
SELL
2026-07-21
50,000.0
$1.0M
Reich Kristian
Chief Scientific Officer
SELL
2026-07-20
43,700.0
$877.9K
Reich Kristian
Chief Scientific Officer
SELL
2026-07-15
16,105.0
$322.3K
97 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 92 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BVF INC/IL
16,001,284.0 sh
$311.5M
Deep Track Capital, LP
6,999,025.0 sh
$136.3M
D. E. Shaw & Co., Inc.
3,365,507.0 sh
$65.5M
Cormorant Asset Management, LP
3,205,433.0 sh
$62.4M
Jupiter Topco LLC
3,085,906.0 sh
$60.1M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Reich Kristian
FILED 2026-07-15
$2.9M
Santos da Silva Jorge
FILED 2026-06-30
$3.0M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
T. Rowe Price Health Care ETF
$181.2K POSITION · AS OF 2026-03-31
0.9%
Virtus Biotech Clinical Trials Etf
$305.7K POSITION · AS OF 2026-04-30
0.8%
ALPS Medical Breakthroughs ETF
$1.1M POSITION · AS OF 2026-02-28
0.8%
Invesco Dorsey Wright Healthcare Momentum ETF
$951.5K POSITION · AS OF 2026-04-30
0.8%
Nomura Healthcare Fund
$1.5M POSITION · AS OF 2026-03-31
0.2%
Optimize Strategy Index ETF
$455.2K POSITION · AS OF 2026-03-31
0.2%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-244.8M$-143.1M$-54.1M$-65.1M
NET INCOME$-227.3M$-118.9M$-36.0M$-50.0M
EPS (DILUTED)-3.53-1.89-0.73-1.70
OPERATING CASH FLOW$-196.0M$-116.6M$-42.8M$-55.9M
CASH$334.5M$180.4M$451.2M$39.5M
LONG-TERM DEBT$74.1M$0——
BUYBACKS—$50$0$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →